Koneksa, a US-based company that develops and implements patient-centric digital biomarkers for drug development, announced on Wednesday that it is extending its collaboration with Sanofi, a France-based global biopharmaceutical company, for central nervous system (CNS) clinical trials.

The collaboration between the firms is intended to support the investigation of tolebrutinib, an investigational Bruton's tyrosine kinase inhibitor, which is an oral, brain-penetrant, selective small molecule presently in Phase III trials for all MS subtypes including Primary Progressive MS (PPMS), Relapsing MS (RMS) and non-relapsing Secondary Progressive MS (nrSPMS).

Rob Ellis, Ph.D., head of Data Science at Koneksa, said, 'Digital endpoints in clinical trials make it possible for researchers to gain insights that were never before within our reach. We're excited for Sanofi to continue incorporating Koneksa's digital biomarker platform into their CNS research.'